GlassScriptPhysician profile
Michael J Mccarthy
NPI 1518421239
$6,941.91
in general payments reported to CMS, 2019-2025
44 companies · $13.99 in 2025
The $13.99 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $2,394 · 2023: $2,515 · 2024: $1,794 · 2025: $13.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.40 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,033.83 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $893.78 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $847.43 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Koya Medical, INC. | $734.74 | 2022 | |
| Lilly USA, LLC | $553.21 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $241.27 | 2022-2024 | |
| Exact Sciences Corporation | $235.39 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $223.02 | 2022-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.28 | 2022-2024 | Synjardy, Jardiance, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $178.18 | 2022-2025 | |
| Amgen INC. | $176.46 | 2022-2024 | Otezla, Repatha, Prolia |
| Novartis Pharmaceuticals Corporation | $143.21 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $137.50 | 2022 | |
| Amneal Pharmaceuticals LLC | $129.15 | 2022-2024 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.87 | 2022-2024 | Trulance, Xifaxan |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $89.70 | 2022-2024 | Tirosint, Licart, Licart |
| Azurity Pharmaceuticals, INC. | $75.62 | 2023 | Edarbi |
| Grt US Holding, INC. | $69.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $58.98 | 2023-2024 | Quviviq |
| Cranial Technologies, INC | $55.47 | 2022-2024 | Doc Band |
| Merck Sharp & Dohme LLC | $52.95 | 2022-2023 | Verquvo, Belsomra |
| Glaxosmithkline, LLC. | $52.29 | 2022-2023 | Shingrix, Bexsero, Pediarix |
| Inspire Medical Systems, INC. | $49.73 | 2023-2024 | Inspire |
| Mannkind Corporation | $42.57 | 2022 | |
| Sumitomo Pharma America, INC. | $42.41 | 2023 | Gemtesa |
| Harmony Biosciences LLC | $41.29 | 2023 | Wakix |
| Neos Therapeutics, LP | $39.71 | 2023-2024 | Adzenys Xr-Odt |
| Renalytix Ai, INC. | $39.35 | 2022-2023 | Kidneyintelx Blood Collection Convenience Kit |
| Averitas Pharma INC. | $38.14 | 2023 | Qutenza |
| Sanofi Pasteur INC. | $37.38 | 2022-2023 | |
| Shield Therapeutics INC | $34.53 | 2023-2024 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $34.13 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.64 | 2022 | |
| Amarin Pharma, INC. | $21.95 | 2022 | |
| Boston Scientific Corporation | $21.78 | 2023 | |
| Dexcom, INC. | $21.08 | 2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $20.22 | 2022 | |
| Esperion Therapeutics, INC. | $19.58 | 2023 | Nexletol |
| Medicure Pharma INC. | $18.97 | 2022 | |
| Tolmar, INC. | $15.64 | 2024 | |
| Edwards Lifesciences Corporation | $14.97 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Takeda Pharmaceuticals U.S.A., INC. | $13.82 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.50 | 2022 | |
| Scilex Pharmaceuticals INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.